📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 17:28
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Nephro Care Q1 PAT ₹1.61 Cr; Fully Utilizes ₹26.15 Cr IPO Funds for Vivacity Hospital
Nephro Care India reported a strong Q1 FY27 with revenue growing 68.4% YoY to ₹29.19 Cr. The company turned profitable with a PAT of ₹1.61 Cr compared to a loss of ₹0.65 Cr in the year-ago period. Operationally, the company has fully utilized its ₹26.15 Cr IPO allocation for the Vivacity Multi-Specialty Hospital and is restructuring its footprint by exiting Tulip Hospital (Ranchi) while entering a new management agreement for Malda Hospital. A regulatory notice from NSE regarding previous half-yearly filing formats is currently under a waiver application.
Confidence: HIGH
What changedThe company has transitioned from a loss-making quarter last year to profitability, completed its primary IPO-funded capex, and optimized its regional hospital portfolio.
Why it mattersThe successful utilization of IPO funds for the multi-specialty hospital marks a transition from a pure renal care player to a broader healthcare provider, which typically commands higher margins and patient stickiness.
Q1 Revenue: ₹29.19 CrQ1 PAT: ₹1.61 CrIPO Capex vs Net Worth: 45.8%IPD Revenue Growth: 103% YoYQ1 Revenue vs FY26 Revenue: 32.9%
📅 Short termThe strong YoY growth and turnaround to profitability are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe shift toward a multi-specialty model (Vivacity) and expansion in Eastern India provides a structural growth path, provided operational efficiencies are maintained.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- NSE notice for non-compliance with Regulation 33 (filing format)
- Execution risk in new hospital management agreements
- High reliance on IPD services growth
Key Highlights
Revenue from operations increased 68.4% YoY to ₹29.19 Cr in Q1 FY27.
Net Profit stood at ₹1.61 Cr for the quarter, a significant turnaround from a ₹0.65 Cr loss in Q1 FY26.
Fully utilized ₹26.15 Cr of IPO proceeds for the flagship Vivacity Multi-Specialty Hospital in Kolkata.
IPD Services revenue grew 103% YoY to ₹15.65 Cr, now contributing over 50% of total revenue.
Strategic shift in Ranchi: Discontinued Tulip Hospital operations while signing a new collaboration with Stone & Urology Clinic.
👀 What to Watch
Investors should monitor the operational breakeven and margin contribution of the newly funded Vivacity Hospital and the outcome of the NSE waiver application regarding filing non-compliance.
Nephro Care Q1 PAT at ₹1.60 Cr; Revenue Grows 68% YoY with Full IPO Fund Deployment
Nephro Care India Limited reported a strong turnaround in Q1 FY27, with a consolidated net profit of ₹1.60 Cr compared to a loss of ₹0.65 Cr in the same quarter last year. Revenue from operations surged 68% YoY to ₹29.18 Cr, driven by a 103% jump in IPD services revenue. The company has successfully deployed ₹26.15 Cr of its IPO proceeds into the Vivacity Multi-Specialty Hospital. Additionally, the board approved a new management agreement for Malda Hospital and a collaboration in Ranchi, while discontinuing operations at the Tulip Hospital in Ranchi.
Confidence: HIGH
What changedThe company has transitioned from a loss-making quarter to profitability while completing the deployment of IPO funds into its flagship hospital project.
Why it mattersThe strong revenue growth and turnaround indicate successful scaling of the clinical network. The shift toward a multi-specialty model (Vivacity) and new management agreements represent a structural expansion of the business beyond pure renal care.
Q1 FY27 Revenue: ₹29.18 CrQ1 FY27 PAT: ₹1.60 CrIPO Fund Utilization (Vivacity): ₹26.15 CrIPD Revenue Growth (YoY): 103%Quarterly Revenue vs Net Worth: ~51%
📅 Short termThe stock is likely to react positively to the strong YoY revenue growth and the turnaround from a loss to a profit.
📈 Long termThe successful deployment of IPO funds and expansion into multi-specialty hospital management could significantly re-rate the business if operational breakeven at Vivacity is sustained.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- NSE notice for non-compliance with Regulation 33 regarding financial result formats
- Discontinuation of operations at Tulip Hospital, Ranchi
Key Highlights
Revenue from operations grew 68.3% YoY to ₹29.18 Cr in Q1 FY27 from ₹17.33 Cr in Q1 FY26.
Turned profitable with a PAT of ₹1.60 Cr against a net loss of ₹0.65 Cr in the previous year's corresponding quarter.
Fully utilized ₹26.15 Cr of IPO proceeds for the Vivacity Multi-Specialty Hospital project.
IPD Services revenue increased significantly to ₹15.65 Cr, contributing over 53% of total revenue.
Board approved a new Hospital Operations & Management Agreement with Prajatna Healthcare for Malda Hospital.
👀 What to Watch
Investors should monitor the operational ramp-up and margin profile of the newly funded Vivacity Multi-Specialty Hospital. Additionally, track the resolution of the NSE notice regarding the reporting format of previous financial results.
